"A growing number of treatments for diseases ranging from cancer to Parkinson's to diabetes depend on modified human cells as the core component of the treatment. These include CAR-T, where a patient's own immune cells are extracted, genetically reprogrammed outside the body so that they can recognize and destroy cancer cells, and then reinjected into the patient. The category also includes various stem cell-based therapies."
"Part of the reason they are so costly is due to the labor-intensive, highly sensitive, and relatively wasteful process that is required to produce them. Scientists have to culture a lot more cells than they need, because some of the cells will not be healthy enough or exhibit the right properties to make a good treatment dose. Although it is possible to determine some aspects of cell health simply by "eyeballing" the living cells under a microscope,"
CellVoyant launched FateView, an AI platform that predicts future health and performance of human cells from microscope images. Many treatments, including CAR-T and various stem cell therapies, depend on modified human cells as the core therapeutic component. Current production requires culturing many more cells than needed because some cells will not meet health or functional criteria, and destructive testing on samples prevents prediction of future cell behavior. The production process is labor-intensive, sensitive, and wasteful, contributing to very high treatment costs. FateView aims to identify promising cells earlier to reduce waste, improve yields, and lower therapy expenses.
Read at Fortune
Unable to calculate read time
Collection
[
|
...
]